About MyOme
MyOme is a company based in San Carlos (United States) founded in 2017 by Kate Im, Akash Kumar, and Matthew Rabinowitz. MyOme has raised $23 million across 1 funding round from investors including Healthcare Ventures. MyOme offers products and services including Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score. MyOme operates in a competitive market with competitors including InformedDNA, Arivale, GB HealthWatch, Answer Genomics and Dante Labs, among others.
- Headquarter San Carlos, United States
- Founders Kate Im, Akash Kumar, Matthew Rabinowitz
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mycarrier Tms
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23 M (USD)
in 1 rounds
-
Latest Funding Round
$23 M (USD), Series B
Jun 21, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MyOme
MyOme offers a comprehensive portfolio of products and services, including Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score.
Assesses personal health risks for prevention and treatment decisions.
Provides testing for rare diseases and exome analysis.
Combines factors for personalized risk assessments across ancestries.
People of MyOme
Unlock access to complete
Unlock access to complete
Funding Insights of MyOme
MyOme has successfully raised a total of $23M through 1 strategic funding round. The most recent funding activity was a Series B round of $23 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MyOme
MyOme has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for MyOme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MyOme
Investment portfolio details for MyOme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MyOme
Detailed financials for MyOme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Myome Comparisons
Peer comparison for MyOme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MyOme
MyOme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as InformedDNA, Arivale, GB HealthWatch, Answer Genomics and Dante Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Network of genetics experts provided to assist patients and providers.
|
|
| Locked | Locked | Locked |
Provider of direct-to-consumer genetic testing.
|
|
| Locked | Locked | Locked |
Personalized nutrition plans are offered via an online health platform.
|
|
| Locked | Locked | Locked |
Online platform offering DNA-based recommendations for health and wellness
|
|
| Locked | Locked | Locked |
Whole-genome sequencing analysis is offered for health and wellness insights.
|
Detailed competitors of MyOme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Myome
Complete news archive for MyOme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MyOme
MyOme was founded in 2017 and raised its 1st funding round 5 years after it was founded.
MyOme is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
MyOme is a funded company, having raised a total of $23M across 1 funding round to date.
MyOme was founded in 2017 and is headquartered in San Carlos, United States. A platform for whole-genome sequencing is offered in the genomics sector to calculate genome risk scores. These scores are used to evaluate risks for common conditions such as heart disease and complex rare disorders influenced by multiple genetic elements. Drug response insights are also generated. Additionally, whole-genome analysis services are available for embryo selection during IVF procedures.
MyOme's top competitors include Dante Labs, InformedDNA and Muhdo.
MyOme offers Proactive Health Tests, Diagnostic Tests, and Integrated Polygenic Risk Score.
MyOme has 1 investor. Key investors include Healthcare Ventures.